What one share of Design Therapeutics holds
We are a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC® molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
Design Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$1.18 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.92 |
| Cash and investments | $3.31 |
| Book value | $3.23 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.01 | −$0.52 | — | — | — | −$0.71 |
| 2021 | — | −$0.77 | $0.03 | −$0.67 | — | $6.89 |
| 2022 | — | −$1.14 | $0.02 | −$0.94 | — | $5.86 |
| 2023 | — | −$1.19 | $0.00 | −$1.05 | — | $4.92 |
| 2024 | $0.00 | −$0.88 | $0.01 | −$0.77 | — | $4.27 |
| 2025 | $0.00 | −$1.22 | $0.00 | −$0.95 | — | $3.52 |
Common questions about Design Therapeutics
How much does one share of Design Therapeutics earn?
Over the last 12 months, Design Therapeutics lost $1.18 for each share.
Does Design Therapeutics pay a dividend?
Design Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Design Therapeutics’s book value per share?
Design Therapeutics’s book value is $3.23 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Design Therapeutics have?
Each share of Design Therapeutics has $3.31 of cash and investments, as of June 30, 2026.
What is Design Therapeutics’s free cash flow per share?
−$0.92 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Design Therapeutics bought back shares?
Design Therapeutics’s share count rose about 263% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.